Illumina Lowers 2015 Revenue Forecast After Missing Q3 Guidance | GenomeWeb

NEW YORK (GenomeWeb) – Illumina expects its third quarter 2015 revenues to be lower than originally anticipated and has lowered its expected full-year revenue growth to 18 percent from its previous estimate of 20 percent, the company said after the close of the market today.

Illumina reported preliminary Q3 revenues of $550 million, a 14 percent increase from $481 million in the third quarter of 2014, but below analysts' average estimate of $568.6 million. On a constant currency basis, Q3 revenues were up 18 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.